HEALIOS K.K. ("Healios") is developing next-generation immuno-oncology therapies, with a focus on solid tumors, using NK cells derived from allogeneic iPSCs and whose specific functions have been enhanced with gene editing technology (development code: HLCN061 "eNK cells"). Healios is executing on its strategy to advance its therapeutic programs while leveraging efficient external funding sources involving investments from third parties including project finance, grants and partnerships.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
137 JPY | -3.52% | -4.20% | -16.97% |
10/04 | Healios Partners with AND Medical Group; Set to Receive Upfront Payment of 60 Million Yen | MT |
09/04 | Healios K.K. Enters into Joint Research Agreement with AND Medical Group | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.97% | 8.18Cr | |
+9.99% | 12TCr | |
+12.01% | 11TCr | |
-3.07% | 2.47TCr | |
-1.08% | 2.2TCr | |
-5.34% | 1.93TCr | |
-6.90% | 1.76TCr | |
-39.36% | 1.73TCr | |
+5.82% | 1.4TCr | |
+33.05% | 1.21TCr |
- Stock Market
- Equities
- 4593 Stock
- News Healios K.K.
- Healios and Saisei Ventures Enter into a Letter of Intent for eNK Research and Development